Are there any new vascepa cost saving options?

Are Existing Patents Impacting Vascepa Cost?

Vascepa, an omega-3 fatty acid medication, is used to lower triglyceride levels in the blood. However, the high price of Vascepa has been a concern for many patients [1]. According to DrugPatentWatch.com, Vascepa's patent EP2774444, covering its active ingredient icosapent ethyl, expires in 2026 in the EU, but the patent situation is complex [2].

Will Biosimilars Offer a Cheaper Alternative?

Biosimilars are generic versions of biologic drugs, similar to generics for traditional chemical medicines. Although Vascepa is not a biologic, its complex formulation makes it difficult to replicate. However, the company Amarin, which produces Vascepa, has agreed not to block the sale of biosimilars in the EU, allowing them to enter the market after the patent expires [3].

How Will This Impact Vascepa's Price?

Since Amarin has agreed to permit the sale of biosimilars, it is likely that this will lead to lower prices for patients in the EU after the patent expires. Biosimilars have been shown to be significantly cheaper than their brand-name counterparts in other cases. However, the exact timing and prices of biosimilars for Vascepa will depend on various factors, including regulatory approvals and market dynamics.

Are There Other Cost-Saving Options Available?

Some patients may be eligible for discounts or coupon programs offered by Amarin or other organizations. Additionally, online pharmacies or patient assistance programs may offer Vascepa at a lower cost. However, these options may have limitations or requirements, such as income or insurance restrictions. Patients are advised to explore these options and consult with their healthcare providers to determine the most cost-effective solution for their specific situation.

Sources:

[1] https://www.drugpatentwatch.com/patent/EP2774444/
[2] https://www.drugpatentwatch.com/patent/EP2774444/
[3] https://www.statnews.com/pharmalot/2017/11/10/amarin-vascepa-biosimilars-icodextrin/